BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 2573426)

  • 1. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.
    Thor AD; Schwartz LH; Koerner FC; Edgerton SM; Skates SJ; Yin S; McKenzie SJ; Panicali DL; Marks PJ; Fingert HJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7147-52. PubMed ID: 2573426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
    McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
    Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
    Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
    Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
    Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
    Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11.
    Dykins R; Corbett IP; Henry JA; Wright C; Yuan J; Hennessy C; Lennard TJ; Angus B; Horne CH
    J Pathol; 1991 Feb; 163(2):105-10. PubMed ID: 1673154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
    van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R
    N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer.
    Schimmelpenning H; Eriksson ET; Falkmer UG; Rutqvist LE; Johansson H; Fallenius A; Auer GU
    Eur J Surg Oncol; 1992 Dec; 18(6):530-7. PubMed ID: 1362164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness.
    Sugano S; Mukai K; Tsuda H; Hirohashi S; Furuya S; Shimosato Y; Ebihara S; Takeyama I
    Laryngoscope; 1992 Aug; 102(8):923-7. PubMed ID: 1353853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
    Giai M; Roagna R; Ponzone R; De Bortoli M; Dati C; Sismondi P
    Anticancer Res; 1994; 14(3B):1441-50. PubMed ID: 7915096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
    Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
    Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.
    Kato T; Kameoka S; Kimura T; Nishikawa T; Kobayashi M
    Anticancer Res; 2002; 22(2B):1097-103. PubMed ID: 12168907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
    Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
    J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
    Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
    Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.